Ascendis Pharma A/S (NASDAQ:ASND) Stock Position Decreased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 17.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 281,537 shares of the biotechnology company’s stock after selling 58,581 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Ascendis Pharma A/S were worth $38,396,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Avoro Capital Advisors LLC increased its stake in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after acquiring an additional 44,580 shares in the last quarter. Capital International Investors raised its holdings in shares of Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after acquiring an additional 10,044 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after acquiring an additional 336,976 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after purchasing an additional 93,185 shares in the last quarter.

Ascendis Pharma A/S Stock Down 1.9 %

Shares of ASND opened at $144.62 on Friday. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of -15.05 and a beta of 0.63. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00. The company’s fifty day moving average is $134.39 and its 200-day moving average is $136.61.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 154.18%. As a group, research analysts predict that Ascendis Pharma A/S will post -7.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ASND has been the subject of a number of research analyst reports. Bank of America increased their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. TD Cowen dropped their target price on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Finally, Jefferies Financial Group increased their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $195.00.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.